Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk
نویسندگان
چکیده
منابع مشابه
Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke
OBJECTIVE To study the early time course of major bleeding and its subtypes in patients with cerebral ischemia on dual and single antiplatelet therapy. METHODS We performed a post hoc analysis on individual patient data from 6 randomized clinical trials (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events [CAPRIE], Second European Stroke Prevention Study [ESPS-2], Management of...
متن کاملAntiplatelet therapy for ischemic heart disease.
Rupture or injury of an atherosclerotic coronary arterial plaque — as occurs spontaneously in patients with an acute coronary syndrome or as the result of a percutaneous coronary intervention — serves as a nidus for platelet aggregation and thrombus formation, which, in turn, may cause myocardial infarction or death. Activation of the platelet-surface glycoprotein IIb/IIIa receptor is the final...
متن کاملGastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy.
GOAL To review the literature on the significance, risk factors, and management of occult and gross gastrointestinal (GI) bleeding in patients on antiplatelets and/or anticoagulants. STUDY Relevant original and review articles and their bibliographies were analyzed. Estimates of risks and therapeutic outcomes were obtained from randomized trials, whereas risk factor identification was gathere...
متن کاملDual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding
BACKGROUND Dual antiplatelet (Plt) therapy with aspirin and clopidogrel is recommended for up to 1 year following acute coronary syndrome. Many of these cardiac patients are also on anithrombotic therapy like warfarin. Lower gastrointestinal bleeding (LGIB) is the main adverse event of this treatment. AIMS The main purpose of this study was to analyze the relationship of dual anti-Plt therapy...
متن کاملIntensity of antiplatelet therapy and percutaneous coronary intervention
Thienopyridine derivatives such as clopidogrel have been shown to reduce the incidence of death in patients undergoing percutaneous coronary intervention when used in conjunction with aspirin. Recently, a new thienopyridine, prasugrel, significantly reduced the primary endpoint of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke to 9.9% compared to 12.1% for clopidogrel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation: Cardiovascular Quality and Outcomes
سال: 2019
ISSN: 1941-7713,1941-7705
DOI: 10.1161/circoutcomes.118.004945